Blurbs

Mizuho Securities Sticks to Their Buy Rating for Humana (HUM)

Mizuho Securities analyst Ann Hynes maintained a Buy rating on Humana (HUMResearch Report) on November 2 and set a price target of $529.00. The company’s shares closed yesterday at $563.00.

According to TipRanks, Hynes is a 5-star analyst with an average return of 8.3% and a 59.74% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Encompass Health, Humana, and Icon.

In addition to Mizuho Securities, Humana also received a Buy from Deutsche Bank’s George Hill in a report issued yesterday. However, on the same day, Truist Financial maintained a Hold rating on Humana (NYSE: HUM).

See Insiders’ Hot Stocks on TipRanks >>

HUM market cap is currently $70.84B and has a P/E ratio of 25.38.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HUM in relation to earlier this year. Last month, Timothy Huval, the CAO of HUM sold 7,437.00 shares for a total of $3,759,403.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services segment.

Read More on HUM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed